Puma Hit With Stock Drop Suit Over Breast Cancer Drug
Puma Biotechnology Inc. was hit with a putative class action for allegedly misleading investors about a new drug application for neratinib, with a California federal court being told Wednesday that Puma...To view the full article, register now.
Already a subscriber? Click here to view full article